Betalin Therapeutics Ltd.

Betalin Therapeutics licensed the novel Engineered Micro Pancreas (EMP) technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development. The EMP aims to restore normal blood glucose levels by mimicking the function of the pancreas using islet cells encapsulated within a micro-organ matrix scaffold. Betalin has produced some promising results and we hope to submit a package soon to the HTA to begin our first in-man studies. which aims to introduce new technologies in the field of cell and gene therapies, and to increase patient access to advanced therapy medicinal products (ATMPs).